Qian Jingbin (April) received her Master degree from the School of International Relations at Beijing Foreign Studies University and with a professional qualification of senior engineer. She joined Tsinghua University in 2010 and has previously worked in various departments and institutions, including THU Office of International Cooperation and Exchange, THU Technology Transfer Institute, and the Beijing Tsinghua Industrial R&D Institute.

During her tenure at the Technology Transfer Institute and Beijing Tsinghua Industrial R&D Institute, Qian Jingbin played a key role in establishing the Global Health Drug Discovery Institute (GHDDI), a joint initiative by Tsinghua University, the Beijing Municipal Government, and the Bill & Melinda Gates Foundation. As China’s first innovation-driven drug research institution focused on global health needs, GHDDI is dedicated to addressing major disease challenges in developing countries, including malaria and tuberculosis. Its establishment filled a critical gap in China’s global health drug R&D sector, creating an innovative platform bridging Chinese research capabilities with international philanthropic organizations and making significant contributions to China’s involvement in global public health governance.

Additionally, as a core team member, she participated in founding other Beijing-based international healthcare innovation platforms, such as the Global Health Industry Innovation Center (GHIC) and the Cell and Gene Therapy Innovation Center (CGTIC). By integrating high-quality domestic and international resources, she put great efforts to build an international innovation chain spanning from technology R&D to industrial transformation, accelerating the commercialization of healthcare advancements and alignment with global standards.